HSK39297
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
Jul 17, 2024 → Apr 2, 2025
NCT ID
NCT06561841About HSK39297
HSK39297 is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT06561841. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06561841 | Phase 2 | Completed |
| NCT06350279 | Phase 1 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |